The OTX-TP travoprost insert showed durable IOP-lowering effect over 12 weeks and a low incidence of the commonly reported side effects of travoprost drops.
The OTX-TP insert (Ocular Therapeutix) was developed with the aim of improving adherence, a critical unmet need with current drop therapies, Srilatha Vantipalli, PhD, said in a study presented at the virtual Association for Research in Vision and Ophthalmology meeting.
“Other issues with chronic use of drops include side effects, for example, hyperemia with travoprost eye drops, difficulty with self-administration and frequent
Uncategorized